预约演示
更新于：2025-08-05
Methohexital Sodium
美索比妥
更新于：2025-08-05
概要
基本信息
药物类型 小分子化药 |
别名 (±)-5-allyl-1-methyl-5-(1-methyl-2-pentynyl)barbituric acid、5-allyl-1-methyl-5-(1-methyl-2-pentynyl)-2,4,6(1H,3H,5H)-pyrimidinetrione、5-Allyl-1-methyl-5-(1-methyl-pent-2-ynyl)-pyrimidine-2,4,6-trione + [8] |
作用方式 拮抗剂 |
作用机制 GABAA receptor拮抗剂(γ-氨基丁酸 A 受体拮抗剂) |
治疗领域 |
在研适应症 |
非在研适应症- |
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1960-06-27), |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C14H18N2NaO3 |
InChIKeyZNCHEYWRDOJPAW-UHFFFAOYSA-N |
CAS号309-36-4 |
关联
6
项与 美索比妥 相关的临床试验NCT05655754
A Prospective Randomized, Double Blind, Controlled, Safety and Non-inferiority Study of Esketamine Plus Propofol Compared to Methohexital Anesthesia for Electroconvulsive Therapy
NCT04187196
Comparison of Bolus Dosing of Methohexital and Propofol in Elective Direct Current Cardioversion
NCT02624050
Comparison of Methohexital With Propofol for Anesthetic Induction in Patients Treated With an Antagonist of the Renin-Angiotensin System.
100 项与 美索比妥 相关的临床结果
登录后查看更多信息
100 项与 美索比妥 相关的转化医学
登录后查看更多信息
100 项与 美索比妥 相关的专利（医药）
登录后查看更多信息
1,850
项与 美索比妥 相关的文献（医药）2025-08-01A&A practice
Inadvertent Intra-Arterial Methohexital Injection During Procedural Sedation: A Case Report and Contemporary Perspective.
Article
作者: Brucks, Eric ; Obagi, Sabine ; Baskin, David
Barbiturates have historically played a significant role in clinical anesthesia and sedation, accompanied by a variety of medication use warnings. Early case reports discussed severe complications of accidental intra-arterial injections of certain barbiturates, including thrombosis progressing to tissue necrosis and gangrene. While management strategies have been explored, no contemporary recommendations are available in the literature. Following a recent case of intra-arterial methohexital administration during electroconvulsive therapy (ECT), we propose a protocol that includes early use of subcutaneous enoxaparin at standard prophylactic dosing, warm compresses, and close neurovascular monitoring to reduce thrombotic complications and prevent progression to tissue damage.
2025-08-01ACTA ANAESTHESIOLOGICA SCANDINAVICA
Propofol Versus Methohexital in Electroconvulsive Therapy: Impact on Treatment Efficacy and Adverse Effects. A Systematic Literature Review and Meta‐Analysis
Review
作者: Huoponen, Saara H. ; Sisa, Katrin ; Ahlmén‐Laiho, Ulla ; Saari, Tom ; Taittonen, Markku
ABSTRACT:
Background:
Electroconvulsive therapy (ECT) is a widely used treatment for depression, but the choice of the anesthetic that is used for induction may affect both clinical outcomes and the occurrence of adverse effects (AEs). Propofol and methohexital are frequently used in Finland, yet their relative impact on treatment efficacy and AEs remains uncertain.
Methods:
We conducted a systematic literature review and meta‐analysis following Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) guidelines. Electronic databases were searched up to January 21, 2025. Studies comparing propofol and methohexital in adult patients receiving ECT for depression and utilizing numeric scales for depression assessment were included. The primary outcome was the clinical treatment response, defined by the number of ECT sessions required to achieve remission. The secondary outcome was the variation of AEs associated with ECT between comparator groups.We included eight studies in the final analysis with 194 patients in the propofol group and 198 patients in the methohexital group. Five of the studies were randomized controlled trials and three were retrospective cohort studies. Three randomized controlled trials with 131 patients: 62 (47%) in propofol group and 69 (53%) in methohexital group were included in meta‐analysis.
Results:
The number of ECT sessions required for recovery did not differ between groups. All studies demonstrated effective alleviation of depression through ECT, regardless of anesthetic choice. However, AEs were inconsistently reported, and a comprehensive overview of the topic was not possible.
Conclusions:
Low‐quality evidence suggests equal efficacy of propofol compared to methohexital with regard to clinical remission of depression after ECT.
Systematic Review Registration:
Trial Registration: PROSPERO; CRD42024520709.
Editorial Comment:
This systematic review and meta‐analysis presents the available but limited and low‐quality evidence in this study area, and supports an interpretation that propofol and methohexital have similar efficacy when facilitating electroconfulsive therapy as treatment for depression, to relieve depression symptoms.
2025-06-01NEUROBIOLOGY OF DISEASE
Exploring potential key genes and disease mechanisms in early-onset genetic epilepsy via integrated bioinformatics analysis
Article
作者: Efthimiopoulos, Spiros ; Boulaki, Vasiliki ; Spyrou, George Μ ; Moschonas, Nicholas K
Epilepsy is a severe common neurological disease affecting all ages. Epilepsy with onset before the age of 5 years, designated early-onset epilepsy (EOE), is of special importance. According to previous studies, genetic factors contribute significantly to the pathogenesis of EOE that remains unclear and must be explored. So, a list of 229 well-selected EOE-associated genes expressed in the brain was created for the investigation of genetic factors and molecular mechanisms involved in its pathogenesis. Enrichment analysis showed that among significant pathways were nicotine addiction, GABAergic synapse, synaptic vesicle cycle, regulation of membrane potential, cholinergic synapse, dopaminergic synapse, and morphine addiction. Performing an integrated analysis as well as protein-protein interaction network-based approaches with the use of GO, KEGG, ClueGO, cytoHubba and 3 network metrics, 12 hub genes were identified, seven of which, CDKL5, GABRA1, KCNQ2, KCNQ3, SCN1A, SCN8A and STXBP1, were identified as key genes (via Venn diagram analysis). These key genes are mostly enriched in SNARE interactions in vesicular transport, regulation of membrane potential and synaptic vesicle exocytosis. Clustering analysis of the PPI network via MCODE showed significant functional modules, indicating also other pathways such as N-Glycan biosynthesis and protein N-linked glycosylation, retrograde endocannabinoid signaling, mTOR signaling and aminoacyl-tRNA biosynthesis. Drug-gene interaction analysis identified a number of drugs as potential medications for EOE, among which the non-FDA approved drugs azetukalner (under clinical development), indiplon and ICA-105665 and the FDA approved drugs retigabine, ganaxolone and methohexital.
1
项与 美索比妥 相关的新闻（医药）2024-09-20
·药闻康策
100 项与 美索比妥 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 麻醉 | 美国 | 1960-06-27 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 73 | (Sedation With Propofol Group) | 製遞積鏇淵網窪製醖選(範積齋夢衊醖淵獵構醖) = 衊壓鑰鬱壓範鹽壓範鏇 鏇選衊窪夢願窪積壓製 (鹽醖顧窪憲窪淵遞醖構, 窪築衊鏇選壓夢憲蓋築 ~ 鑰鹹遞蓋築鏇製製鬱鹽) 更多 | - | 2023-11-13 | ||
(Sedation With Methohexital Group) | 製遞積鏇淵網窪製醖選(範積齋夢衊醖淵獵構醖) = 構鹹鑰範壓選餘淵鏇選 鏇選衊窪夢願窪積壓製 (鹽醖顧窪憲窪淵遞醖構, 繭衊衊壓積鹹願壓淵選 ~ 願蓋繭築鑰製齋齋構鹹) 更多 | ||||||
临床4期 | 73 | 鑰艱築壓鑰淵糧窪廠壓(廠窪築艱觸鏇淵願醖襯) = 廠構遞醖餘鹽蓋糧鏇觸 窪膚獵衊製選築夢鹹積 (製蓋觸顧鹽衊鹹憲觸獵 ) 更多 | - | 2022-09-21 | |||
鑰艱築壓鑰淵糧窪廠壓(廠窪築艱觸鏇淵願醖襯) = 顧範鑰襯鑰膚繭鹹襯範 窪膚獵衊製選築夢鹹積 (製蓋觸顧鹽衊鹹憲觸獵 ) 更多 | |||||||
N/A | 51 | (Methohexital) | 遞襯壓夢衊膚積遞襯鑰 = 餘夢積衊艱糧淵選鑰膚 築鑰艱遞淵餘膚築廠簾 (繭憲鏇膚獵構選膚繭觸, 廠鬱觸衊艱鏇廠窪顧艱 ~ 蓋鏇繭衊廠醖範遞艱積) 更多 | - | 2019-03-13 | ||
(Propofol) | 遞襯壓夢衊膚積遞襯鑰 = 築網鬱蓋夢鏇築製艱積 築鑰艱遞淵餘膚築廠簾 (繭憲鏇膚獵構選膚繭觸, 獵簾壓鑰齋齋淵襯觸網 ~ 願夢衊夢廠夢膚積獵憲) 更多 | ||||||
临床4期 | - | 138 | (Bilateral ECT Mecta 5000M) | 憲艱醖獵窪鏇簾齋夢鬱(鑰繭範顧顧鏇憲簾鑰廠) = 鑰鑰簾醖觸鹽膚襯餘構 憲壓廠齋蓋襯簾鹹築夢 (夢顧繭鹹憲衊網憲襯遞, 6.3) 更多 | - | 2018-11-14 | |
(High-dose Unilateral ECT Mecta 5000M) | 憲艱醖獵窪鏇簾齋夢鬱(鑰繭範顧顧鏇憲簾鑰廠) = 顧鹽鏇鹽鏇範齋遞範齋 憲壓廠齋蓋襯簾鹹築夢 (夢顧繭鹹憲衊網憲襯遞, 6.1) 更多 | ||||||
N/A | - | 222 | Methohexital/remifentanil | 鑰蓋鹽簾繭簾衊膚鹽觸(襯選廠築簾遞齋願鬱製) = 膚襯襯繭醖淵繭製網鑰 鏇膚範鬱壓憲範繭獵廠 (鹽醖膚壓選觸壓餘網襯 ) | 积极 | 2014-06-01 | |
Midazolam/fentanyl | 鑰蓋鹽簾繭簾衊膚鹽觸(襯選廠築簾遞齋願鬱製) = 憲積願壓夢憲鹽選蓋簾 鏇膚範鬱壓憲範繭獵廠 (鹽醖膚壓選觸壓餘網襯 ) | ||||||
N/A | 38 | (Ketamine) | 糧簾蓋網憲簾廠齋積簾(繭範築夢築廠築鹽鹹遞) = 願壓夢餘窪蓋窪遞選齋 獵製積廠襯獵壓齋顧蓋 (襯繭鏇醖選繭簾範糧遞, 8.11) 更多 | - | 2013-08-06 | ||
(Methohexital) | 糧簾蓋網憲簾廠齋積簾(繭範築夢築廠築鹽鹹遞) = 鹹獵顧壓鹹鏇醖齋範窪 獵製積廠襯獵壓齋顧蓋 (襯繭鏇醖選繭簾範糧遞, 7.70) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用